Yuan 2014.

Methods	Allocation: randomised. Blindness: double‐blind.
Participants	Diagnosis: first episode schizophrenia (DSM‐IV).
Interventions	Intervention: Stage 1: Risperidone (3 mg to 6 mg/day), aripiprazole (15 mg to 30 mg/day) or olanzapine (10 mg to 25 mg/day). Stage 2: Change the current antipsychotic to one of the other two study drugs. Stage 3: pharmacotherapy could be switched to any other atypical antipsychotic including long‐acting medications. Furthermore, a combination with other antipsychotics or a certain adjunctive antidepressant was allowed for patients who still could not reach satisfactory outcome after the previous 2 stages. If the treatment failed as judged by the investigators and/or the patient, the patients entered the next stage of the trial.
Outcomes	Clinical response: CGI‐S and CGI‐I and < 50% reduction on the total score of the PANSS. Mental state: PANSS. Adverse events: UKU side‐effect scale. Treatment adherence: DAI. Social functions: Personal and Social Performance scale. Cognitive performance.
Notes	No response from responsible contact Xin Yu (yuxin@bjmu.edu.cn).

BACS ‐ Brief Assessment of Cognition in Schizophrenia.
 BAS ‐ Barnes Akathisia Scale.
 BPRS ‐ Brief Psychiatric Rating Scale.
 CCMD ‐ Chinese Classification of Mental Disorders.
 CGI‐I ‐ Clinical Global Impression ‐ Improvement.
 CGI‐S ‐ Clinical Global Impression ‐ Severity.
 DAI ‐ Drug Attitude Inventory.
 DSM ‐ Diagnostic and Statistical Manual of Mental Disorders.
 IM ‐ intramuscular.
 IMI‐SR ‐ Intrinsic Motivation Inventory for Schizophrenia Research.
 MRI ‐ magnetic resonance imaging.
 PANSS ‐ Positive and Negative Syndrome Scale.
 SWN ‐ Subjective Well Being under Neuroleptics.
 UKU ‐ Udvalg for Kliniske Undersøgelser.